Panacea Biotec has secured a $20 million long-term loan from the US International Development Finance Corporation to expand its hexavalent vaccine production. This funding will help the company meet global demand for childhood immunization, supplying vaccines to UN agencies. The hexavalent vaccine, EasySix, protects against six diseases and is expected to see significant demand growth by 2030.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.